Abstract
Introduction
The use of injectable fillers in facial cosmetic procedures has become extremely popular over the past decade. These materials are considered an excellent addition to the armamentarium of the cosmetic medical provider, as they allow for a minimally invasive approach to facial reconstruction and rejuvenation. In view of the minimally invasive nature of these products, patients and providers alike might approach these injections with the notion that they represent a low-risk procedure, but they are not without potentially significant drawbacks.
Our goal in presenting this article is to highlight one of the significantly deforming complications that may result from the use of certain injectable fillers. We describe the known complications of facial cosmetic silicone injections with a focus on granuloma formation. In addition, we cite several case reports from the literature that have detailed various aspects of silicone granuloma formation, based on our extensive 10-year review of the recent literature. It is our hope to increase awareness of the problem and thereby minimize potential harm to patients.
Silicone is a versatile material that is used frequently in biomedical procedures. Its use dates back as early as the 1940s, when it was first described for breast augmentation in Japan. 1, 2 Its most common form is polydimethylsiloxane, also known as dimethicone and silicone oil, and it is available in solid, gel, and liquid forms:
• In its solid form, silicone is an elastomer-an elastic covalently cross-linked polymer network that is used in implantable prosthetics and intravenous-fluid tubing. 3 • As a gel, silicone exists swollen in solvent and may be cross-linked, which allows it to exhibit properties of both its solid and liquid forms. Silicone gels are used primarily in breast augmentation.
• In its liquid state, silicone typically exists in low-molecular-weight forms. While it is used primarily in ophthalmology and is approved only for use in the retina, 4 liquid silicone also has been used for soft-tissue injections in facial, gluteal, and breast cosmetic applications, although its use in these circumstances is still off-label. In addition to being injectable, the advantageous biologic qualities of liquid silicone include the facts that it is inert, noncarcinogenic, and inexpensive.
Silicone is just one of many biomaterials used for cosmetic facial injections, but unlike hyaluronic acid, collagen, and calcium hydroxyapatite, silicone had not been granted FDA approval for these applications. Some
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physicians have advocated the regulated use of silicone in view of its ability to provide long-lasting cosmetic corrections. 5, 6 The FDA has recently approved several clinical trials to establish the safety and efficacy of silicone under controlled conditions. 7 Even though silicone is biologically inert, its injection can result in the formation of granulomas.
8 Silicone granulomas were first described in 1964 as a rare complication that was, and continues to be, a diagnostic challenge. 9 The severity and frequency of granuloma formation, as well as other immunologic complications, will likely increase if injections are administered by incautious or unqualified, perhaps unlicensed, practitioners using non-medical-grade silicone.
The popularity of administering liquid silicone injections as a dermal filler in facial cosmetic procedures has fluctuated. Injectable silicone's primary functions have been to reduce glabellar, nasolabial, and marionette skin lines, to camouflage scars, and to augment the lips. The microdroplet technique allows for the administration of liquid silicone at 1-month intervals so that clinicians can assess gradual improvement incrementally.
Small amounts of injection have traditionally been associated with good results. 10 However, in some cases, they have been associated with relatively minor complications, including pain, swelling, erythema, ecchymosis, pigmentation, induration, and deformity from material migration. 11 Migration of injected silicone may occur over the course of years, leading to an accumulation of particles and nodular granulomas at sites far removed from the points of injection. Over time, many of these complications may resolve, with or without conservative treatment measures. However, because silicone is a permanent filler, nodules and granulomas, particularly in the lips, will not resolve without direct excision.
With larger injections, which are typically administered to the gluteal region and chest wall, more serious complications have been reported, including cellulitis, 12 ulceration and necrosis, 12 abscess, 13, 14 lymphadenopathy, 15, 16 pneumonitis, 17 hepatitis, 18 toxic shock syndrome, 19 systemic sclerosis, 20 end-organ failure, 21 and embolization leading to sudden death 22 and blindness. 23 Most recently, Lee et al documented a case of lymphoma after silicone injection. 24 In that case, extranodal marginal-zone B-cell lymphoma of MALT (mucosaassociated lymphoid tissue) arose in a 72-year-old woman who had received a silicone injection in her cheek. This suggests that chronic inflammation secondary to the injection might trigger adverse immunologic reactions and tumorigenesis.
Complications of silicone injections can occur immediately, within 3 weeks, within a year, or as long as decades after treatment. Although catastrophic complications are rare, physicians always should be careful not to inject silicone into vasculature and to use appropriate injection techniques to minimize risk. Some rare immunologic complications include pseudocyst formation, fibrosis, and eosinophilia. 13 However, the most commonly described immunologic and histologic finding is granuloma formation.
As mentioned, silicone granulomas, also called siliconomas, were first described in 1964; Winer et al reported them as representing a dermal immunologic response to silicone injection in 3 patients. 9 Clinically, these lesions present as a subcutaneous nodule that can be either local or located at a distance from the site of injection. Most granulomas form within the first 12 months after injection; common sites are the lips, nose, and chin. 25, 26 The diagnosis of silicone granuloma can be made only by pathologic confirmation, but a history of cosmetic injections should raise a clinician's suspicion. Ultrasonography, computed tomography, and/or magnetic resonance imaging can demonstrate pertinent anatomic boundaries. It is important to distinguish a silicone granuloma from orofacial granulomatosis, which is a granulomatous process that leads to persistent swelling and enlargement of the mouth and lips. 27, 28 As is the case with any foreign-substance injection, the body reacts through both an acute and chronic inflammatory response (figure). The acute phase is characterized by migration of neutrophils and protein exudate, while the chronic phase involves lymphocyte and monocyte aggregation. In particular, the monocytes differentiate into macrophages, and they induce a granulomatous response through signaling by a constellation of cytokines, including interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α). 29 In general, the granulomatous response to silicone is variable. It usually manifests as a central region of macrophages surrounded by a zone of lymphocytes and a zone of fibroblasts. The presence of both epithelioid macrophages and multinucleated foreign-body giant cells with centrally arranged nuclei is a classic histologic feature. 19 Collagen deposition by fibroblasts is often a desired side effect because it can tighten sagging skin. Vacuolated macrophages can also mimic lipoblasts and liposarcomas histologically. 30 Because such responses can also be seen in liposarcoma, which can have a complicated and extensive treatment plan, a history of cosmetic injections, particularly long-standing or unregulated, should be elicited.
In silicone-induced inflammation, it is unclear whether the immune system is responding to the silicone itself or to additives or contaminants, which have been reported to include fumed silica, an amorphous aggregate of silica, and platinum. 31 Fumed silica has previously been shown to be highly immunogenic in an animal model. 32 
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Previous studies have demonstrated that silicone can induce an antigen-specific response in and of itself, perhaps as a result of hydrophobicity. 33 However, they have also demonstrated that the immune response is significantly enhanced by additional antigens that are present alongside the silicone, suggesting that contamination or additives might be responsible. This theory is supported by the fact that a small fraction of granulomas that form in response to silicone injections are infectious granulomas. 34 Despite the ability of granulomas to wall off silicone, unencapsulated silicone may leak to regional or distant lymph nodes and travel to other parts of the body, where it can cause adverse immunologic phenomena.
Literature review
We reviewed the PubMed database using the search term silicone granuloma to identify articles published from September 2007 through September 2017. We then selected all articles that involved silicone granulomas that arose as a result of cosmetic injections in the face; articles involving silicone granulomas elsewhere were excluded.
Our search identified 180 different kinds of reports on silicone granulomas; of these, 15 involved cosmetic silicone injections in the face. 8, 10, 20, 23, [26] [27] [28] 30, [35] [36] [37] [38] [39] [40] [41] We also included a single as-yet-unpublished case that is currently in press. 42 What follows is a synopsis of some of the more interesting cases:
Hu et al described a case of delayed-onset silicone granuloma formation in the nose and periorbital eye that had arisen 40 years after the patient had received a silicone implant in conjunction with liquid silicone. 35 The patient did not respond to antibiotics, although systemic steroids were effective in limiting symptoms. For treatment, the patient underwent rhinoplasty using irradiated costal cartilage and had the silicone implant and surrounding tissue removed. This case shows that a granulomatous reaction can occur decades after the initial injection and suggests that physicians need to acknowledge the potential for this complication for the entire duration of a patient's life.
Chen et al described a similar complication that also occurred 40 years after an injection. 36 In this case, a woman had received silicone for chin augmentation. She had been initially diagnosed with angioedema mimicking total facial swelling, but she was later was found to have silicone granulomas that had spread all over her face. In another case in which surgical involvement was precluded, Crocco et al reported successful treatment with systemic minocycline monotherapy. 37 Another highly interesting case demonstrating the delayed onset of silicone granuloma formation was described in 2014 by Eun et al. 38 They reported the case of a 62-year-old woman in South Korea who had presented with a disfigured nose. The disfiguration involved thickening and lichenification of the nasal root and the upper two-thirds of the nose, which resulted in an elephant trunk-like appearance. Forty years earlier, the patient had been illegally injected with a filler by an unlicensed practitioner to correct a flat nose bridge. After her nose had been thickened, she was subsequently administered a "dissolving" agent, which eventually culminated in her disfiguration. On histology, she was found to have a granulomatous response that involved mononuclear cells, lipid-laden macrophages, and foreign-body giant cells, with spherules of lipid consistent with sclerosing lipogranuloma, most likely from a silicone injection. This case demonstrates the
Figure. Illustration depicts the foreign-body response to silicone that leads to encapsulation and granuloma formation. The response involves an initial inflammatory response dominated by neutrophils, which leads to a fibrous encapsulation that is initiated by responses from fibroblasts and macrophages. (FBGCs = foreign-body giant cells.)
Reproduced with permission from the Nature Publishing Group.
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potential for sclerosing granulomas to cause serious disfigurement.
Similarly, Friedmann et al reported the formation of granulomas that formed in response to either polymethylmethacrylate or liquid silicone in 4 patients who had been injected between 15 months and 5 years earlier. 39 They postulated the formation of biofilms and argued that silicone provides a surface upon which microorganisms can adhere. They suggested the use of polymerase chain reaction testing for biofilm detection on silicone injectables.
Woodward et al added polyacrylamide and poly-L-lactic acid to the list of injectables that can cause granulomas because of their ability to serve as a nidus for biofilm formation. 40 They also suggested a novel treatment that had been earlier proposed by Kornstein 43 in which ultrasonography is used to break apart silicone nodules to prevent granuloma formation and spread.
Rongioletti et al described the cases of 2 women in Italy who developed diffuse facial nodular tumefaction after silicone injections. 41 One patient presented with a leonine face after receiving an illegal injection of what she had been told was Juvederm, a hyaluronic acid product. A punch biopsy revealed that she had developed a siliconoma, for which she was treated with minocycline. Another patient presented with multiple painful nodules in her periorbital and perioral areas; she had also received silicone under the impression that it was hyaluronic acid. She was also treated with minocycline.
The 2 cases reported by Rongioletti et al highlight the dangers of receiving injections by unlicensed providers and the fact that a filler purported to be hyaluronic acid might actually be the much more dangerous silicone. We have also seen this complication in one of our own patients who had received such an injection by an unlicensed provider. 42 In another report illustrating the same idea, Ellis et al described 2 cases of granuloma formation after silicone injection. 8 A 39-year-old man presented with subcutaneous nodules in his nasolabial folds 5 weeks after he had received injections from a nurse at a day spa. The product was purported to be Restylane, a hyaluronic acid product. The patient failed to respond to numerous treatments, including a low-dose steroid, tacrolimus, imiquimod, and pulsed-dye laser therapy. The granulomas were finally treated successfully with the use of high-dose intralesional steroid injections, but the patient required ongoing cycles of treatment.
In the other case described by Ellis et al, a 57-year-old woman developed swellings in her lips after she had undergone lip augmentation by an unlicensed provider. 8 Histology suggested silicone granuloma formation, and the patient was treated with a combination of pulsed-dye laser therapy, pimecrolimus cream, a calcineurin inhibitor, and low-dose intralesional steroid injections. This is yet another example of how silicone injections are often misrepresented as FDA-approved fillers and used illicitly by unlicensed providers, resulting in great harm to patients.
Finally, Sanchis-Bielsa et al reported a series of 15 cases of granuloma formation from cosmetic injections, one of the largest series on granuloma formation to date. 26 They treated 14 women and 1 man who had developed a foreign-body granulomatous reaction in response to the injection of cosmetic materials. To highlight silicone's prevalence as a primary factor in causing these complications, 9 of these 15 cases had been caused by silicone. In these patients, systemic steroids rather than intralesional steroids were used to control symptoms with great success.
Discussion
Silicone granulomas are as prevalent as they have always been, but there is no consensus regarding their treatment. Treatment can be difficult and in many cases unsuccessful. Clinicians should try to individualize treatment for each patient. If surgical excision is deemed necessary, significant scarring can be expected because the silicone itself and the granulomas can migrate throughout multiple layers of soft tissue, often necessitating the removal of thick sections of tissue. In some patients, granulomas will resolve spontaneously without treatment.
The more common treatments include systemic and local steroids, 3 minocycline, 16,37 5-fluorouracil, 44 isotretinoin 45 and, for localized granuloma formation, surgical resection. While success has been achieved with steroids, relapse often occurs after a steroid taper. Consideration should be given to whether an oral or intralesional steroid would be more appropriate. Patients with disseminated granulomas or with multiple lesions may need an oral steroid. The antimetabolite 5-fluorouracil has also been successful in conjunction with triamcinolone. 44 Antibiotics, especially minocycline, have been used successfully for their anti-inflammatory and antigranulomatous properties, as well as their mycobacterial coverage. Their use has been enhanced with the addition of celecoxib. 46 Isotretinoin is also used for its anti-inflammatory properties and dermatologic efficacy.
More specific treatment modalities that are targeted directly to granulomas include imiquimod and etanercept. Imiquimod acts by modulating IFN-γ. 47 Etanercept is a TNF-α inhibitor that directly prevents granuloma formation. 48 There have been reports of success with the use of both in treating silicone granulomas.
Surgical resection is a good option for localized granulomas, although the resected tissue must be replaced to fill the dead space and minimize postoperative aesthetic deformity.
There is not enough literature detailing the causal mechanisms of silicone granulomas, and there are wANG, ThOMAS, fRieDMAN various explanations on how they form. Silicone formulations can be highly heterogeneous, necessitating some standardization in the way silicone is manufactured. Finally, as we have seen, some unlicensed practitioners are providing silicone injections as a dermal filler, often misleading patients into believing that they are receiving an FDA-approved hyaluronic-acid-based product such as Juvederm or Restylane. Physicians should be aware of these inappropriate uses.
In conclusion, the popularity of injectable fillers has increased dramatically over the past decade. Many nonphysicians and some poorly trained physicians perform injectable filler procedures to capitalize on the significant financial incentives associated with this practice. Patients are attracted to injectable fillers because of their noninvasive method of administration. However, practitioners sometime perform these procedures cavalierly, at times ignoring the potential for serious complications.
We write this report to inform otolaryngologists of the need to weigh the risks and benefits of injectable fillers, especially silicone. There are significant potential downsides to the administration of injectable fillers, and providers and patients alike must be made aware of both the short-and long-term risks. Granuloma formation after liquid silicone injections should be considered in the differential diagnosis of any patient with a history of cosmetic injections who has developed inflammatory masses. Granulomas form because of foreign-body reactions to silicone that lead to fibrous encapsulation and deposition of a dense collagenous fibrous matrix.
The three most common cell types implicated in this process are lymphocytes, macrophages, and fibroblasts. Silicone granulomas can be managed both medically and surgically, but in nearly all cases, they will leave some degree of permanent scar deformity.
